Utilities and disutilities for type 2 diabetes treatment-related attributes

IntroductionAlthough cost-utility analyses are frequently used to estimate treatment outcomes for type 2 diabetes, utilities are not available for key medication-related attributes. The purpose of this study was to identify the utility or disutility of diabetes medication-related attributes (weight change, gastrointestinal side effects, fear of hypoglycemia) that may influence patient preference.MethodsPatients with type 2 diabetes in Scotland and England completed standard gamble (SG) interviews to assess utility of hypothetical health states and their own current health state. The EQ-5D, PGWB, and Appraisal of Diabetes Symptoms were administered. Construct validity and differences among health states were examined with correlations, t-tests, and ANOVAs.ResultsA total of 129 patients (51 Scotland; 78 England) completed interviews. Mean utility of diabetes without complications was 0.89. Greater body weight was associated with disutility, and lower body weight with added utility (e.g., 3% higher = −0.04; 3% lower = +0.02). Gastrointestinal side effects and fear of hypoglycemia were associated with significant disutility (p < 0.001). SG utility of current health (mean = 0.87) demonstrated construct validity through correlations with patient-reported outcome measures (r = 0.08–0.31).DiscussionThe vignette-based approach was feasible and useful for assessing added utility or disutility of medication-related attributes.

[1]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[2]  I. McDowell,et al.  Measuring health: A guide to rating scales and questionnaires, 3rd ed. , 2006 .

[3]  P. Krabbe,et al.  Guidelines for analysing and reporting EQ-5D outcomes , 2003 .

[4]  G. Torrance.  Preferences for health outcomes and cost-utility analysis. , 1997, The American journal of managed care.

[5]  P. Stalmeier.  Utilities and patient preferences discrepancies between chained and classic utilities induced by anchoring with occasional adjustments , 2002 .

[6]  E. Brähler,et al.  Der Lebensqualitätsfragebogen EQ-5D: Modelle und Normwerte für die Allgemeinbevölkerung , 2005 .

[7]  A. Scheen,et al.  Treatment of diabetes in patients with severe obesity. , 2000, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  L. Matza,et al.  Health State Utilities for Childhood Attention-Deficit/Hyperactivity Disorder Based on Parent Preferences in the United Kingdom , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  Dennis A. Revicki,et al.  Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report , 2003, Quality of Life Research.

[10]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[11]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[12]  J. Peters,et al.  Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) , 2006, Current medical research and opinion.

[13]  M. Engelgau,et al.  Valuing health-related quality of life in diabetes. , 2002, Diabetes care.

[14]  S. Heller.  Weight gain during insulin therapy in patients with type 2 diabetes mellitus. , 2004, Diabetes research and clinical practice.

[15]  David M Eddy,et al.  Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes , 2005, Annals of Internal Medicine.

[16]  R. S. Jorgensen,et al.  Reliability and validity of the Appraisal of Diabetes Scale , 1991, Journal of Behavioral Medicine.

[17]  M. Johannesson,et al.  Health State Utilities in Gastroesophageal Reflux Disease Patients with Heartburn: A Study in Germany and Sweden , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  P. Kekki,et al.  Performance of two measures of general health-related quality of life, the EQ-5D and the RAND-36 among critically ill patients , 2004, Intensive Care Medicine.

[19]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[20]  G W Torrance,et al.  Incorporating Utility-Based Quality-of-Life Assessment Measures in Clinical Trials: Two Examples , 1989, Medical care.

[21]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[22]  J. Garrow,et al.  Quetelet's index (W/H2) as a measure of fatness. , 1985, International journal of obesity.

[23]  D Cheţa,et al.  Fear of hypoglycemia in type 1 (insulin-dependent) diabetic patients. , 1993, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[24]  Maureen,et al.  Methodological Issues of Patient Utility Measurement Experience From Two Clinical Trials , 1995, Medical care.

[25]  D. Foxcroft,et al.  Orlistat for the treatment of obesity: rapid review and cost‐effectiveness model , 2000, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[26]  Peter P. Wakker,et al.  A Study of the Chained Procedure for the Standard Gamble and Time Tradeoff , 2008 .

[27]  J. Foreyt,et al.  Validity and Reliability of the General Well-Being Schedule with Northern Plains American Indians Diagnosed with Type 2 Diabetes Mellitus , 2003, Psychological reports.

[28]  C. Weyer,et al.  Properties of pramlintide and insulin upon mixing. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[29]  J. Brazier,et al.  A comparison of the EQ-5D and SF-6D across seven patient groups. , 2004, Health economics.

[30]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[31]  H. König,et al.  [The Quality of Life Questionnaire EQ-5D: modelling and norm values for the general population]. , 2006, Psychotherapie, Psychosomatik, medizinische Psychologie.

[32]  R. Taylor,et al.  NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE) , 2002, International Journal of Technology Assessment in Health Care.

[33]  D. Feeny,et al.  A Comparison of the Health Utilities Indices Mark 2 and Mark 3 in Type 2 Diabetes , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  C. Currie,et al.  Evaluation of the association between the EQ‐5Dindex (health‐related utility) and body mass index (obesity) in hospital‐treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes , 2005 .

[35]  M. Johannesson,et al.  Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[36]  Frank de Charro,et al.  The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective , 2003, Springer Netherlands.

[37]  A Gafni,et al.  The standard gamble method: what is being measured and how it is interpreted. , 1994, Health services research.

[38]  Jackie Brown,et al.  Valuing temporary and chronic health states associated with breast screening. , 1998, Social science & medicine.

[39]  Deanna J. M. Isaman,et al.  A computer simulation model of diabetes progression, quality of life, and cost. , 2005, Diabetes care.

[40]  B. Spilker,et al.  Quality of life and pharmacoeconomics in clinical trials , 1996 .

[41]  M. Koopmanschap.  Coping with Type II diabetes: the patient’s perspective , 2002, Diabetologia.

[42]  J. L. Pinto,et al.  A Consistency Test of the Time Trade-Off , 2003 .

[43]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[44]  D A Revicki,et al.  Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. , 1998, Journal of affective disorders.

[45]  A. Bagust,et al.  Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. , 2005, Health economics.

[46]  Subjective health values of individuals with diabetes in Japan: comparison of utility values with the SF-36 scores. , 2003, Diabetes research and clinical practice.

[47]  C. Tack,et al.  Pathophysiology and management of recurrent hypoglycaemia and hypoglycaemia unawareness in diabetes. , 2006, The Netherlands journal of medicine.

[48]  D. Feeny,et al.  Utilities and Quality-Adjusted Life Years , 1989, International Journal of Technology Assessment in Health Care.

[49]  Knut Stavem,et al.  Quality of life in epilepsy: comparison of four preference measures , 1998, Epilepsy Research.

[50]  Volker Foos,et al.  The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making , 2004, Current medical research and opinion.

[51]  Haomiao Jia,et al.  The impact of obesity on health-related quality-of-life in the general adult US population. , 2005, Journal of public health.

[52]  E. Barrett-Connor,et al.  Body mass index and quality of well-being in a community of older adults. , 2004, American journal of preventive medicine.

[53]  C. van Weel,et al.  Insulin therapy in poorly controlled type 2 diabetic patients: does it affect quality of life? , 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

[54]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[55]  S. Shakir,et al.  Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study , 2005, Osteoporosis International.

[56]  R. Holman,et al.  Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) , 2005, Diabetologia.

[57]  C. Weyer,et al.  Weight Effect of Current and Experimental Drugs for Diabetes Mellitus , 2003, Treatments in endocrinology.

[58]  J. Richardson,et al.  A cost utility analysis of treatment options for gallstone disease: methodological issues and results. , 1994, Health economics.

[59]  D. Feeny,et al.  Health and Quality of Life Outcomes , 2003 .

[60]  D. Osoba.  Effect of Cancer On Quality of Life , 1991 .

[61]  E P Steinberg,et al.  Comparison of the Rating Scale and the Standard Gamble in Measuring Patient Preferences for Outcomes of Gallstone Disease , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[62]  E. Juniper,et al.  Comparison of the standard gamble, rating scale, AQLQ and SF-36 for measuring quality of life in asthma. , 2001, The European respiratory journal.

[63]  G. Dailey,et al.  Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study , 2004, Current medical research and opinion.

[64]  G P Samsa,et al.  The Relationship Between Glycemic Control and Health‐Related Quality of Life in Patients With Non‐Insulin‐Dependent Diabetes Mellitus , 1994, Medical care.

[65]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[66]  J. Albu,et al.  The management of the obese diabetic patient. , 2003, Primary care.

[67]  C. Beverley,et al.  Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. , 2004, Health technology assessment.

[68]  R. Heine,et al.  Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes , 2005, Annals of Internal Medicine.

[69]  D. Feeny,et al.  Health utility estimation , 2002, Expert review of pharmacoeconomics & outcomes research.

[70]  P. Leigh,et al.  Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis , 2003, Quality of Life Research.

[71]  G. Torrance.  Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.

[72]  N. Jones,et al.  Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire , 1993, Quality of Life Research.

[73]  L Gonder-Frederick,et al.  Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus. , 1992, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[74]  C. Furberg,et al.  Assessment of quality of life in clinical trials of cardiovascular therapies. , 1984, The American journal of cardiology.

[75]  N. Fineberg,et al.  Fear of Hypoglycemia in the Parents of Children and Adolescents With Diabetes: Maladaptive or Healthy Response? , 1997, The Diabetes educator.

[76]  M. Koopmanschap,et al.  Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. , 2002, Diabetes care.

[77]  Alastair Gray,et al.  Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62) , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.